Form 4: Abeona Therapeutics CFO Acquires 144,509 Shares of Restricted Stock

Abeona Therapeutics' Chief Financial Officer, Joseph Walter Vazzano, acquired 144,509 shares of restricted stock on January 21, 2025.

Summary

• Joseph Walter Vazzano, the Chief Financial Officer of Abeona Therapeutics, acquired 144,509 shares of restricted common stock on January 21, 2025.
• The acquisition was a grant of restricted stock, with a price of $0.00 per share.
• Following the transaction, Mr. Vazzano beneficially owns 509,726 shares of Abeona Therapeutics common stock.
• The restricted stock will vest in three equal installments on January 21, 2026, January 21, 2027, and January 21, 2028.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, but the acquisition of shares by the CFO is a positive sign of confidence in the company. The sentiment is therefore slightly positive.

Positives

• The acquisition of shares by the CFO demonstrates confidence in the company's future prospects.
• The vesting schedule of the restricted stock aligns the CFO's interests with the long-term performance of the company.

Risks

• The vesting of the restricted stock is contingent on Mr. Vazzano's continued employment with the company.
• The value of the stock is subject to market fluctuations and the company's performance.

Future Outlook

The document does not contain any forward-looking statements or guidance.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when officers or directors acquire or dispose of company stock. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• Stock grants to executives are a common practice in publicly traded companies, particularly in the biotech industry.
• The vesting schedule of one-third annually over three years is a typical structure for restricted stock grants.
• The size of the grant is not unusual for a CFO of a company of this size, but without further context, it is difficult to compare to specific benchmarks.

Stakeholder Impact

• The stock acquisition may be viewed positively by shareholders as it aligns the CFO's interests with the company's performance.
• The vesting schedule may encourage the CFO to remain with the company for the long term.

Key Dates

Keywords

Abeona Therapeutics, stock acquisition, restricted stock, insider trading, CFO, Joseph Vazzano, beneficial ownership, vesting